Table 4. Results of the TKI treatment according to the EGFR mutations.

	Group1 MT in PT & LN	Group2 MT in PT & WT in LN	Group3 majMT in PT & LN	Group4 majMT in PT & WT in LN	Group5 WT in PT & LN
PR+SD	17/23(73.9%)	2/3(66.7%)	16/19(84.2%)	2/3(66.7%)	3/16 (18.8%)
PD	6/23(26.1%)	1/3(33.3%)	3/19(15.8%)	1/3(33.3%)	13/16(81.2%)

TKI; tyrosine kinase inhibitor, MT; any mutation, majMT; major mutation, WT; wild type, PR; partial response, SD; stable disease, PD; progressive disease

Group 1 vs. Group 2; p = 1.00, Group3 vs. Group4; p = 0.47, Group 1+2 vs. Group5, p = 0.001, Group 3+4 vs. Group5, p = 0.0002